Not feeling well? Give us a call before you come in.

Effective March 23, 2020: Gundersen suspends all hospital and clinic visitors

There is no panel matching the key "MicroAlert"

Cancer & Blood Disorders Clinical Trials

Gundersen Health System has about 100 research studies available for cancer patients at any given time.

NCORP badge

With support from Gundersen Medical Foundation, the Cancer and Blood Disorders Center offers research studies through participation in regional and national cancer treatment cooperative groups. By sharing clinical research efforts and measuring collective results, treatments are advanced more rapidly than any institution can accomplish alone. Participation in these groups can shorten the time it takes for us to get new, more effective drugs on the market.

Sometimes patients are concerned that if they don't get the experimental therapy, they will only get a placebo. However, in cancer research, the patient will either get the standard treatment or the new experimental drug that has shown signs to be potentially better than the standard treatment. Not everyone will qualify for a cancer research study, but for those who do, it can offer new hope.

Brain/Central Nervous System Cancer

  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS)
    Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
  • Alliance N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade
    Glioma
  • COG ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
    • *AGE: ≥ 3 years and < 22 years of age at the time of enrollment
  • COG ACNS1721: A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600 Mutations
    • *AGE: Stratum 2 (IDH mutant): ≥ 3 years of age and ≤ 25 years of age at the time of enrollment.
  • Wake Forest WF 1801: A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Breast Cancer

EARLY STAGE

Neoadjuvant

  • No Neoadjuvant trials at this time

Inflammatory

  • SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer.

Adjuvant

  • Alliance A011401 (BWEL): Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL)
  • Alliance A011502 (ABC): A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
  • Alliance A211601: Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502
  • Alliance A221505 (RT): Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
  • CCTG.MA.39 TailorRT (RT): Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (TAILOR RT)
  • ECOG EA1131(TNBC): A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
  • NRG-BR003 (TNBC): A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
  • NRG-CC004 - Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
  • NRG NSABP B-51 (RT): A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
  • SWOG S1418 (TNBC): A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
  • Wake Forest WF-97116: A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment

ADVANCED/METASTATIC

  • Alliance A171601: (≥70 years old) A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Gastrointestinal Cancer

COLON

Adjuvant

  • A021502: Randomized Trial of Standard Chemotherapy
    Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
  • SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Metastatic

  • NRG-GI004: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
  • SWOG S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification (Suspended 5/16/2019)
  • SWOG S1609:"DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Other

  • ECOG ACRIN EAQ162CD: Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

RECTAL

Adjuvant

  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Metastatic/Advanced

  • NRG-GI004: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
  • SWOG S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification (Suspended 5/16/2019)
  • SWOG S1609:"DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Other

  • ECOG ACRIN EAQ162CD: Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

ANAL

  • ECOG ACRIN EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

CHOLANGIOCARCINOMA

  • SWOG S1815 - A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

PANCREATIC

  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

GASTRIC

  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

ESOPHAGEAL

  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

HEPATIC

  • COG AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
    • *AGE: ≤ 30 years of age at the time of diagnosis
  • COG ADVL1622: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
    • *AGE: ≥ 2 and ≤ 30 years of age at the time of study entry for all strata except upper age limit of ≤ 18 years of age for MTC, RCC and HCC
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Genitourinary Cancer

BLADDER

Adjuvant

  • Alliance A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Neoadjuvant

  • Alliance A031701: A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
  • SWOG S1602: A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection

Metastatic/Advanced

  • SWOG S1602: A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH:Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

PROSTATE

  • NRG-GU005: Phase II IGRT And SRBT Vs IGRT And Hypofractionated IMRT For Localised Intermediate Risk Prostate Cancer
  • Wake Forest WF-1802 - Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

RENAL

  • COG ADVL1622: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
    • *AGE: ≥ 2 and ≤ 30 years of age at the time of study entry for all strata except upper age limit of ≤ 18 years of age for MTC, RCC and HCC.
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Germ Cell Tumors

  • COG AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
    • *AGE: Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites)) Patients must be < 50 years of age at enrollment.
    • Standard Risk 1 Patients must be < 11 years of age at enrollment.
    • Standard Risk 2 Patients must be ≥ 11 and < 25 years of age at enrollment.
  • COG AGCT1532: A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors
    • *AGE: ≥ 11 years and ≤ 45 years on the date of randomization
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH:Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Gynecological Cancer

CERVICAL

  • GOG 0263: Phase III Randomized Study of Adjuvant Radiation Versus Chemoradiation Therapy in Patients With Intermediate-Risk Stage I-IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
  • RTOG 0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiotherapy With Versus Without Adjuvant Chemotherapy in Patients With High-Risk Early-Stage Cervical Carcinoma After Radical Hysterectomy
  • NRG-CC004 - Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH:Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

ENDOMETRIAL

  • GOG 0238: Phase II Randomized Study of Pelvic Radiotherapy With Versus Without Cisplatin in Patients With Recurrent Endometrial Cancer
  • Lunchbox: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel for Optimally Debulked Advanced Endometrial Carcinoma
  • NRG-CC004 - Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH:Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE

  • NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
  • NRG-CC004 - Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

CERVICAL

  • GOG 0263: Phase III Randomized Study of Adjuvant Radiation Versus Chemoradiation Therapy in Patients With Intermediate-Risk Stage I-IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
  • RTOG 0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiotherapy With Versus Without Adjuvant Chemotherapy in Patients With High-Risk Early-Stage Cervical Carcinoma After Radical Hysterectomy
  • NRG-CC004 - Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH:Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

ENDOMETRIAL

  • GOG 0238: Phase II Randomized Study of Pelvic Radiotherapy With Versus Without Cisplatin in Patients With Recurrent Endometrial Cancer
  • Lunchbox: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel for Optimally Debulked Advanced Endometrial Carcinoma
  • NRG-CC004 - Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH:Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE

  • NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
  • NRG-CC004 - Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Head and Neck Cancer

  • ECOG-ACRIN EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
  • NRG-HN001: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
  • NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin
  • NRG-HN005: A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH:Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Leukemia

ACUTE LEUKEMIA

ALL

  • COG AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome (DS) B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
    • *AGE: ≥ 365 days and < 10 years of age (B-ALL patients without DS)
    • ≥ 365 days and ≤ 31 years of age (B-ALL patients with DS)
    • ≥ 365 days and ≤ 31 years of age (B-LLy patients with or without DS)
  • COG AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
    • *AGE: > 1 year and < 21 years at ALL diagnosis
  • The Gundersen Lutheran Bio-Bank Project I: Collection of Biological Specimens for Medical Research from Patients with Blood and Marrow Disorders

AML

  • Connect® MDS/AML Disease Registry (Celgene NCI-2015-01815)
  • The Gundersen Lutheran Bio-Bank Project I: Collection of Biological Specimens for Medical Research from Patients with Blood and Marrow Disorders

APL

  • ECOG-ACRIN EA9131: Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia
  • The Gundersen Lutheran Bio-Bank Project I: Collection of Biological Specimens for Medical Research from Patients with Blood and Marrow Disorders

CHRONIC LEUKEMIA

  • A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
  • EA9161: A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger (< 70) Patients with Chronic Lymphocytic Leukemia (CLL)
  • The Gundersen Lutheran Bio-Bank Project I: Collection of Biological Specimens for Medical Research from Patients with Blood and Marrow Disorders

Lung Cancer

NSCLC (Non-Small Cell Lung Cancer)

  • Alliance A151216: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (ALCHEMIST Treatment Trial)
    • Sub Studies for A151216:
      • Alliance A081105: Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
      • ECOG E4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
  • ECOG EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis
  • NRG-LU002: Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
  • SWOG LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
    • Sub Studies for LUNGMAP:
      • SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)
      • SWOG S1800A (A LUNG-MAP Non-Matched Sub-Study) - A Phase II Randomized Study of Ramucirumab Plus Mk3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
      • SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

SMALL CELL LUNG CANCER

  • NRG-CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
  • NRG – LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

MESOTHELIOMA

  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Lymphoma

HODGKIN'S

  • SWOG S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.
  • ECOG-ACRIN E4412: A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

NON-HODGKIN'S

Diffuse Large B-Cell Lymphoma

  • Alliance A051701: Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double-Expressing Lymphomas
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Follicular Lymphoma

  • SWOG S1608: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma- Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in treating patients with relapsed or refractory grad I-IIIa Follicular Lymphoma
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Lymphoblastic Lymphoma

  • COG AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome (DS) B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
    • *AGE: ≥ 365 days and < 10 years of age (B-ALL patients without DS)
    • ≥ 365 days and ≤ 31 years of age (B-ALL patients with DS)
    • ≥ 365 days and ≤ 31 years of age (B-LLy patients with or without DS)

Mantle Cell Lymphoma

Upfront:

  • ECOG EA4181: A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 years old with Untreated Mantle Cell Lymphoma
  • ECOG-ACRIN EA4151: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab alone for patients with Mantle Cell Lymphoma in minimal residual disease- negative first complete remission
  • PrECOG PrE0405: Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

Relapsed/Refractory:

  • PrECOG PrE0404: Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Melanoma

ADJUVANT

  • No Trials Available

ADVANCED

First Line

  • ECOG EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab +Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib +Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
  • SWOG S1616: A Phase II Randomized Study of Nivolumab
    (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1Agent
    • Eligible if recurrent while receiving adjuvant PD-1 or PD-L1 therapy
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Second Line

  • SWOG S1616: A Phase II Randomized Study of Nivolumab
    (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1Agent
    • Eligible if disease progression while on or have stopped anti-PD1 or anti-PD-L1 agents
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Multiple Myeloma

SMOLDERING MYELOMA

  • ECOG-ACRIN EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering (DETER-SMM)

MYELOMA

First Line

  • No Trials Available

Relapsed

  • Alliance A061202: Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy

Myelodysplastic Syndrome

Neuroblastoma

  • COG ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
    • *AGE: ≥ 365 days and ≤ 30 years of age at diagnosis
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Pediatric and Young Adult Oncology

BRAIN

  • COG ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
    • *AGE: ≥ 3 years and < 22 years of age at the time of enrollment
  • COG ACNS1721: A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600 Mutations
    • *AGE: Stratum 2 (IDH mutant): ≥ 3 years of age and ≤ 25 years of age at the time of enrollment.
  • COG ACCL10P1: Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study
    • *AGE: 6 to 16 years at study enrollment, inclusive
  • COG APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
    • *AGE: ≥ 12 months and ≤ 21 years of age at the time of study enrollment

LEUKEMIA

ALL

  • COG AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
    • *AGE: ≥ 365 days and < 10 years of age (B-ALL patients without DS)
    • ≥ 365 days and ≤ 31 years of age (B-ALL patients with DS)
    • ≥ 365 days and ≤ 31 years of age (B-LLy patients with or without DS)
  • COG AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
    • *AGE: > 1 year and < 21 years at ALL diagnosis
  • COG APEC14B1: Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
    • *AGE: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for which there is a higher upper age limit.

AML

  • COG AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
    • *AGE: > 90 days and < 4 years of age at diagnosis of AML or Myelodysplastic Syndrome (MDS)
  • COG APEC14B1: Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
    • *AGE: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for which there is a higher upper age limit

LYMPHOMA

  • SWOG S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.
    • *AGE: ≥ 12 years of age
  • COG AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
    • *AGE: ≥ 365 days and < 10 years of age (B-ALL patients without DS)
    • ≥ 365 days and ≤ 31 years of age (B-ALL patients with DS)
    • ≥ 365 days and ≤ 31 years of age (B-LLy patients with or without DS)
  • COG APEC14B1: Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
    • *AGE: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for which there is a higher upper age limit.
  • COG APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
    • *AGE: ≥ 12 months and ≤ 21 years of age at the time of study enrollment

NEUROBLASTOMA

  • COG ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
    • *AGE: ≥ 365 days and ≤ 30 years of age at diagnosis
  • COG ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
    • *AGE: < 12 months (< 365 days) of age at diagnosis with INRG Stage L1; or < 18 months (< 547 days) of age at diagnosis with INRG Stage L2 or Stage Ms neuroblastoma/ganglioneuroblastoma.
  • COG ANBL00B1: Neuroblastoma Classification Biology Studies
  • COG APEC14B1: Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
    • *AGE: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for which there is a higher upper age limit.
  • COG APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
    • *AGE: ≥ 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621G: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621H: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621I: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621J: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment

SARCOMAS

  • COG ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
    • *AGE: ≤ 40 years of age at the time of enrollment
  • COG ADVL1622: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
    • *AGE: ≥ 2 and ≤ 30 years of age at the time of study entry for all strata except upper age limit of ≤ 18 years of age for MTC, RCC and HCC.
  • COG APEC14B1: Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
    • *AGE: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for which there is a higher upper age limit.
  • COG APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
    • *AGE: ≥ 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusions
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of tazemetostat for patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621D: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LY3023414 in Solid Tumors
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621E: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)– Phase 2 subprotocol of Selumetinib in patients with Tumors harboring activating MAPK pathway mutations
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621G: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621H: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621I: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621J: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment

OTHER (KIDNEY, LIVER, RETINO, GCT, RARE)

  • COG AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
    • *AGE: ≤ 30 years of age at the time of diagnosis
  • COG AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
    • *AGE: Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites)) Patients must be < 50 years of age at enrollment
    • Standard Risk 1 Patients must be < 11 years of age at enrollment
    • Standard Risk 2 Patients must be ≥ 11 and < 25 years of age at enrollment.
  • COG AGCT1532: A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors
    • *AGE: ≥ 11 years and ≤ 45 years on the date of randomization
  • COG ADVL1622: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
    • *AGE: ≥ 2 and ≤ 30 years of age at the time of study entry for all strata except upper age limit of ≤ 18 years of age for MTC, RCC and HCC.
  • COG APEC14B1: Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
    • *AGE: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for which there is a higher upper age limit.
  • COG APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
    • *AGE: ≥ 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusions
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of tazemetostat for patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621D: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LY3023414 in Solid Tumors
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621E: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)– Phase 2 subprotocol of Selumetinib in patients with Tumors harboring activating MAPK pathway mutations
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621G: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621H: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621I: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
  • COG APEC1621J: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
    • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment

LATE EFFECTS

  • COG ALTE03N1: Key Adverse Events after Childhood Cancer
    • *AGE: Diagnosis of primary cancer at age 21 or younger, irrespective of current age
  • COG ALTE07C1: Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer
    • *AGE: All ages
  • COG ALTE15N2: LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
    • *AGE: ≥ 5 and ≤ 50 years of age at study enrollment
  • COG ALTE1631: A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Cancer
    • *AGE: ≥ 8 years of age and < 16 years of age at time of enrollment

Precision Medicine

  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
    • ARCUS: Phase 1b open-label study to evaluate the safety and clinical activity of AB122 in biomarker-selected participants with advanced solid tumors. Uses StrataNGS to identify TMB – High or SIS – High cohorts
    • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
    • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Prevention/Symptom Management

Sarcoma

  • COG ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
    • *AGE: ≤ 40 years of age at the time of enrollment
  • COG ADVL1622: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
    • *AGE: ≥ 2 and ≤ 30 years of age at the time of study entry for all strata except upper age limit of ≤ 18 years of age for MTC, RCC and HCC.
  • SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Screenings

  • EA1151 TMIST: Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

If you are interested in getting additional information on a research study, please contact:

Lori Meyer, RN, OCN, CCRC
(608) 775-2579 or (800) 362-9567, ext. 52579
lameyer@gundersenhealth.org

Christine Roraff, RN
(608) 775-7001 or (800) 362-9567, ext. 57001
cmroraff@gundersenhealth.org

Jonean Thorsen, RN
(608) 775-7001 or (800) 362-9567, ext. 57001
jethorse@gundersenhealth.org

Love + Medicine

Every day, Gundersen Health System staff deliver great medicine plus a little something extra—we call it Love + Medicine.

Share Your Story